Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.Clin Nutr 2016; 35(3):578-86CN
Abstract
BACKGROUND
& aims: Few clinical trials have addressed the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) on non-alcoholic steatohepatitis (NASH). We evaluated the effects of supplementation with omega-3 PUFAs from flaxseed and fish oils in patients with biopsy-proven NASH.
METHODS
Patients received three capsules daily, each containing 0.315 g of omega-3 PUFAs (64% alpha-linolenic [ALA], 16% eicosapentaenoic [EPA], and 21% docosahexaenoic [DHA] acids; n-3 group, n = 27) or mineral oil (placebo group, n = 23). Liver biopsies were evaluated histopathologically by the NASH activity score (NAS). Plasma levels of omega-3 PUFAs were assessed as a marker of intake at baseline and after 6 months of treatment. Secondary endpoints included changes in plasma biochemical markers of lipid metabolism, inflammation, and liver function at baseline and after 3 and 6 months of treatment.
RESULTS
At baseline, NAS was comparable between the groups (p = 0.98). After intervention with omega-3 PUFAs, plasma ALA and EPA levels increased (p ≤ 0.05). However in the placebo group, we also observed increased EPA and DHA (p ≤ 0.05), suggesting an off-protocol intake of PUFAs. NAS improvement/stabilization was correlated with increased ALA in the n-3 group (p = 0.02) and with increased EPA (p = 0.04) and DHA (p = 0.05) in the placebo group. Triglycerides were reduced after 3 months in the n-3 group compared to baseline (p = 0.01).
CONCLUSIONS
In NASH patients, the supplementation of omega-3 PUFA from flaxseed and fish oils significantly impacts on plasma lipid profile of patients with NASH. Plasma increase of these PUFAs was associated with better liver histology. (ID 01992809).
MeSH
BiomarkersBiopsyBrazilDietary SupplementsDouble-Blind MethodFatty Acids, Omega-3FemaleFish OilsHospitals, TeachingHumansHypertriglyceridemiaLinseed OilLiverLost to Follow-UpMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePatient CompliancePatient DropoutsReproducibility of ResultsSeverity of Illness Index
Pub Type(s)
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
26047766
Citation
Nogueira, Monize Aydar, et al. "Omega-3 Polyunsaturated Fatty Acids in Treating Non-alcoholic Steatohepatitis: a Randomized, Double-blind, Placebo-controlled Trial." Clinical Nutrition (Edinburgh, Scotland), vol. 35, no. 3, 2016, pp. 578-86.
Nogueira MA, Oliveira CP, Ferreira Alves VA, et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2016;35(3):578-86.
Nogueira, M. A., Oliveira, C. P., Ferreira Alves, V. A., Stefano, J. T., Rodrigues, L. S., Torrinhas, R. S., ... Waitzberg, D. L. (2016). Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition (Edinburgh, Scotland), 35(3), pp. 578-86. doi:10.1016/j.clnu.2015.05.001.
Nogueira MA, et al. Omega-3 Polyunsaturated Fatty Acids in Treating Non-alcoholic Steatohepatitis: a Randomized, Double-blind, Placebo-controlled Trial. Clin Nutr. 2016;35(3):578-86. PubMed PMID: 26047766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
AU - Nogueira,Monize Aydar,
AU - Oliveira,Claudia Pinto,
AU - Ferreira Alves,Venâncio Avancini,
AU - Stefano,José Tadeu,
AU - Rodrigues,Lívia Samara Dos Reis,
AU - Torrinhas,Raquel Susana,
AU - Cogliati,Bruno,
AU - Barbeiro,Hermes,
AU - Carrilho,Flair José,
AU - Waitzberg,Dan Linetzky,
Y1 - 2015/05/21/
PY - 2014/09/23/received
PY - 2015/03/27/revised
PY - 2015/05/08/accepted
PY - 2015/6/7/entrez
PY - 2015/6/7/pubmed
PY - 2018/1/18/medline
KW - Alpha-linolenic acid
KW - Docosahexaenoic acid
KW - Eicosapentaenoic acid
KW - Fish oil
KW - Flaxseed oil
KW - Nonalcoholic steatohepatitis
SP - 578
EP - 86
JF - Clinical nutrition (Edinburgh, Scotland)
JO - Clin Nutr
VL - 35
IS - 3
N2 - BACKGROUND: & aims: Few clinical trials have addressed the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) on non-alcoholic steatohepatitis (NASH). We evaluated the effects of supplementation with omega-3 PUFAs from flaxseed and fish oils in patients with biopsy-proven NASH. METHODS: Patients received three capsules daily, each containing 0.315 g of omega-3 PUFAs (64% alpha-linolenic [ALA], 16% eicosapentaenoic [EPA], and 21% docosahexaenoic [DHA] acids; n-3 group, n = 27) or mineral oil (placebo group, n = 23). Liver biopsies were evaluated histopathologically by the NASH activity score (NAS). Plasma levels of omega-3 PUFAs were assessed as a marker of intake at baseline and after 6 months of treatment. Secondary endpoints included changes in plasma biochemical markers of lipid metabolism, inflammation, and liver function at baseline and after 3 and 6 months of treatment. RESULTS: At baseline, NAS was comparable between the groups (p = 0.98). After intervention with omega-3 PUFAs, plasma ALA and EPA levels increased (p ≤ 0.05). However in the placebo group, we also observed increased EPA and DHA (p ≤ 0.05), suggesting an off-protocol intake of PUFAs. NAS improvement/stabilization was correlated with increased ALA in the n-3 group (p = 0.02) and with increased EPA (p = 0.04) and DHA (p = 0.05) in the placebo group. Triglycerides were reduced after 3 months in the n-3 group compared to baseline (p = 0.01). CONCLUSIONS: In NASH patients, the supplementation of omega-3 PUFA from flaxseed and fish oils significantly impacts on plasma lipid profile of patients with NASH. Plasma increase of these PUFAs was associated with better liver histology. (ID 01992809).
SN - 1532-1983
UR - https://www.unboundmedicine.com/medline/citation/26047766/Omega_3_polyunsaturated_fatty_acids_in_treating_non_alcoholic_steatohepatitis:_A_randomized_double_blind_placebo_controlled_trial_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(15)00131-4
DB - PRIME
DP - Unbound Medicine
ER -
